 Acurx Pharmaceuticals CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his companyNew York, New York--Newsfile Corp. - September 13, 2021 - Acurx Pharmaceuticals NASDAQ: ACXP is a clinical-stage biopharmaceutical company developing a new class of antibiotics that could present the most meaningful changes to that sector in more than four decades. Its lead program utilizes ibezapolstat to target the debilitating C. difficile infection. Other pipeline programs and drugs are expected to target and treat numerous other gram-positive infections.That strategy could be advantageous on several fronts and... 